Tilray Inc. ($TLRY) Stock Forecast: Down 6.0% Today

What is Tilray Inc.?

Tilray Brands, Inc. (TLRY) is a global lifestyle and consumer packaged goods company focusing on cannabis, beverage, and wellness sectors. The company is set to announce its financial results for the second fiscal quarter ending November 30, 2025, which has generated significant market interest.

Why is Tilray Inc. going down?

TLRY stock is down 6.0% on Dec 22, 2025 20:35

• The bearish movement in TLRY stock today could be attributed to the anticipation and uncertainty surrounding the upcoming financial results announcement.
• Comments on Tilray's lack of earnings may have contributed to investor skepticism and selling pressure on the stock.
• Despite the positive news about Tilray's formation of Tilray Medical USA, Inc. to advance its U.S. medical cannabis operations, the overall market sentiment may have been overshadowed by concerns about the company's financial performance and growth strategy.
• The market might be reacting to the realization that Tilray's growth is primarily driven by acquisitions in the alcohol sector rather than its struggling cannabis segment, raising doubts about the company's long-term sustainability.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray Brands, Inc. to Announce Second Fiscal Quarter Financial Results on January 8, 2026

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) will announce its financial results for the second fiscal quarter ending November 30, 2025, after market close on January 8, 2026. A live conference call and audio webcast will follow at 4:30 PM ET, where investors can submit questions via Robinhood and Say Technologies until January 7, 2026. Tilray is a global lifestyle and consumer packaged goods company focusing on cannabis, beverage, and wellness sectors.

https://www.quiverquant.com/news/Tilray+Brands%2C+Inc.+to+Announce+Second+Fiscal+Quarter+Financial+Results+on+January+8%2C+2026

Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026

Tilray Brands will release its financial results for the second fiscal quarter, ending November 30, 2025, after the market closes on Thursday, January 8, 2026. The company will host a live conference call and webcast to discuss these results at 4:30 PM Eastern Time on the same day, with investors able to submit questions in advance.

https://finance.yahoo.com/news/tilray-brands-announce-second-quarter-120000799.html

Is Tilray Brands Stock a Buy, Sell, or Hold in 2026?

Tilray Brands stock is highly volatile and risky, with its performance heavily reliant on potential U.S. marijuana reform, specifically rescheduling rather than outright legalization. Despite recent optimism due to President Trump considering rescheduling, Tilray's Canadian base means rescheduling alone won't open the U.S. market for its marijuana products. The company's financial results are troubling, showing a net loss and cash burn, with growth primarily driven by acquisitions in the alcohol sector rather than its struggling cannabis segment.

https://www.fool.com/investing/2025/12/19/is-tilray-stock-a-buy-sell-or-hold-in-2026/

Jim Cramer on Tilray: “What They Lack Is Earnings”

Jim Cramer succinctly advised a caller to sell half of their Tilray Brands (NASDAQ:TLRY) stock immediately and the remaining half if it gets approved, emphasizing the company's lack of earnings. Tilray recently launched new cannabis products through its acquired brand Redecan, including Amped Live Resin Liquid Diamond 1g 510 cartridges. Despite these product developments, the article suggests that certain AI stocks may offer better upside potential and less risk compared to Tilray.

https://finance.yahoo.com/news/jim-cramer-tilray-lack-earnings-201412087.html

How a global cannabis provider is gearing up for a new era in U.S. care

Tilray Brands announced the formation of Tilray Medical USA, Inc. to advance its U.S. medical cannabis operations following federal rescheduling. The company plans to leverage its global experience, including over 200 registered medical cannabis products and participation in 15+ clinical studies, to lead innovation and growth in the evolving U.S. market. Tilray's CEO, Irwin D. Simon, highlighted the decision to reschedule cannabis as a significant catalyst for positive change and a critical step towards comprehensive regulation in the U.S.

https://www.stocktitan.net/news/TLRY/tilray-accelerates-u-s-medical-cannabis-expansion-after-landmark-4m58a2nokpgh.html

Trending Today

Xerox Corporation ($XRX) Stock Forecast: Down 5.7% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 6.0% Today

First Solar Inc. ($FSLR) Stock Forecast: Up 6.8% Today

Dominion Energy Inc. ($D) Stock Forecast: Down 0.9% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Down 5.3% Today

Norwegian Cruise Line Holdings Ltd. ($NCLH) Stock Forecast: Up 5.0% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.1% Today

Cassava Sciences, Inc. ($SAVA) Stock Forecast: Up 6.3% Today

Cronos Group Inc. ($CRON) Stock Forecast: Down 5.1% Today

Fastly Inc. ($FSLY) Stock Forecast: Up 5.3% Today

Tilray Inc. Price History

09.11.2025 - TLRY Stock was up 7.0%

• The launch of Tilray's Ultimate 2025 Holiday Drink Gift Guide featuring festive beverages may have sparked investor interest, hinting at potential expansion in the company's product range and consumer appeal.
• Following recent declines linked to internal changes, the stock saw a successful recovery, hitting a new 1-year peak, potentially influenced by heightened investor trust in Tilray's strategies and market position.
• Today's positive market outlook for Tilray could also be attributed to the overall industry optimism in the cannabis sector, with investors eyeing growth prospects in a sector shaped by changing consumer tastes and regulations.

22.11.2025 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today could be attributed to the company's ongoing financial struggles, lack of earnings, and cash burn.
• Despite recent positive sentiment and stock rises driven by potential easing of marijuana restrictions and strategic developments, the market may be reacting to the underlying financial challenges faced by Tilray.
• The uncertainty surrounding U.S. marijuana reform, particularly the reliance on federal rescheduling rather than outright legalization, might be causing investors to exercise caution and reevaluate their positions in Tilray.

22.11.2025 - TLRY Stock was down 6.0%

• The bearish movement in TLRY stock today could be attributed to the anticipation and uncertainty surrounding the upcoming financial results announcement.
• Comments on Tilray's lack of earnings may have contributed to investor skepticism and selling pressure on the stock.
• Despite the positive news about Tilray's formation of Tilray Medical USA, Inc. to advance its U.S. medical cannabis operations, the overall market sentiment may have been overshadowed by concerns about the company's financial performance and growth strategy.
• The market might be reacting to the realization that Tilray's growth is primarily driven by acquisitions in the alcohol sector rather than its struggling cannabis segment, raising doubts about the company's long-term sustainability.

19.11.2025 - TLRY Stock was down 8.4%

• There was a significant bearish movement in TLRY stock today, possibly due to investors cashing out profits following a recent surge triggered by indications of potential marijuana reclassification by a former President.
• Market reaction may be influenced by experts warning that moving cannabis to Schedule III doesn't mean federal legalization, causing uncertainty and prompting selling.
• Despite forming Tilray Medical USA, Inc. to expand U.S. medical cannabis operations, the company's financial difficulties, ongoing losses, and focus on alcohol acquisitions rather than cannabis growth could be fueling negative market sentiment.
• The uncertain regulatory landscape for cannabis, paired with a recent reverse split and general market instability, may be intensifying downward pressure on Tilray's stock price.

03.11.2025 - TLRY Stock was down 10.1%

• Tilray's stock has experienced a 24% drop over the past five sessions due to corporate restructuring and a reverse stock split.
• Negative company developments, including the reverse stock split and market pressures, have influenced the downward movement in TLRY's stock.
• Despite positive Q1 cannabis growth and a strengthened domestic position, the adverse effects of corporate changes have outweighed the positive news, leading to ongoing downward pressure on the stock.
• Investor response to Tilray's uncertainties and obstacles has caused the stock to decline further in line with broader market conditions.

16.11.2025 - TLRY Stock was up 5.8%

• TLRY experienced a substantial surge of 44.1% following potential discussions of a reclassification of marijuana at a federal level. This positive news not only impacted TLRY but also other cannabis stocks like Canopy Growth and Aurora Cannabis.
• The company's recent execution of a 10-for-1 reverse stock split, aimed at reducing its float and ensuring compliance with Nasdaq regulations, also influenced the bullish movement by boosting investor confidence.
• Surpassing its 200-day moving average and holding a Zacks Rank #3 (Hold) indicate a potential long-term bullish trend for TLRY, supported by positive earnings estimate revisions and strategic expansion into new markets.
• While the future looks promising, caution is advised due to the volatility in the cannabis sector. It is advisable for investors to closely monitor the situation until official confirmation and details regarding the potential policy change are disclosed.

17.11.2025 - TLRY Stock was down 8.1%

• Despite positive developments regarding the potential reclassification of marijuana from Schedule I to Schedule III, Tilray faced a bearish movement.
• The surge in Tilray's stock price post speculations on marijuana reclassification by Trump might have prompted profit-taking actions among investors, leading to the bearish movement.
• Uncertainty surrounding the final reclassification decision and profit-taking activities likely contributed to Tilray's stock price decline today.
• The market sentiment towards Tilray remains optimistic, anticipating future ease in federal restrictions and potential improvements in profitability.

17.11.2025 - TLRY Stock was up 16.2%

• TLRY stock surged by 44.1% due to speculation about a possible reclassification of marijuana as a Schedule III substance through an executive order.
• The surge in TLRY's stock price was driven by optimism about relaxed federal restrictions on cannabis and the potential business opportunities it could bring for companies in the industry.
• Despite the initial rally, the stock price cooled off as White House officials indicated that no final decision had been reached, showcasing the uncertainty surrounding the potential reclassification of marijuana. This led to profit-taking and a moderation in TLRY's price movement.
• Tilray's CEO emphasized the importance of clear regulation in the cannabis industry, especially regarding THC-infused drinks. He highlighted how regulatory clarity could benefit legitimate companies by ensuring quality standards and reducing illicit market activity.

12.11.2025 - TLRY Stock was up 31.7%

• The introduction of Redecan's Amped Live Resin Liquid Diamond 1g 510 cartridges in Canada has sparked enthusiasm and market interest, contributing to Tilray's upward movement.
• Positive developments related to the legalization of home marijuana cultivation in Florida and potential changes in federal cannabis regulations have bolstered investor confidence in Tilray's future outlook.
• Despite facing challenges such as increased expenses and a stock price decline, Tilray's expansion strategies and focus on evolving into a diversified consumer packaged goods (CPG) company have resonated well with traders and investors, driving the bullish market performance observed today.
• The company's adept handling of regulatory shifts and its ability to seize opportunities within the cannabis sector are expected to be key factors influencing its stock performance in the immediate future.

15.11.2025 - TLRY Stock was down 5.2%

• The bearish movement in TLRY today could be attributed to profit-taking by investors after a series of strong bullish movements.
• Despite the recent surge in TLRY's stock price, the lack of a definitive catalyst or news today may have led to a natural correction in the market.
• The mixed views from analysts regarding TLRY's future performance, balancing policy tailwinds with execution challenges, could have also contributed to the bearish movement as investors reassess the stock's potential.

10.11.2025 - TLRY Stock was up 12.0%

• Despite recent difficulties, Tilray (TLRY) witnessed a notable upward movement in the market today.
• This positive shift could be linked to the company's recent initiatives to expand into areas beyond its core cannabis business, such as broadening its beverage and hemp-derived THC product offerings.
• Investors seem hopeful about Tilray's potential for profitability despite ongoing losses, particularly with its focus on non-cannabis sectors to enhance profit margins.
• Today's optimistic market trend may also be driven by speculation regarding potential policy changes concerning the reclassification of cannabis, which could potentially benefit Tilray's future performance.

19.11.2025 - TLRY Stock was down 23.1%

• Today's bearish movement in TLRY may be due to investors taking profits following a recent surge influenced by discussions of President Trump contemplating cannabis reclassification.
• Though there is optimism about regulatory changes, the speculative nature of the cannabis industry and uncertainties regarding federal legalization may be causing some traders to proceed with caution.
• Volatility in TLRY's stock price could be impacted by option traders anticipating significant year-end movements, leading to short-term market fluctuations.
• It is important for investors to stay informed about any official announcements on cannabis regulations to navigate the current market volatility effectively.